Published in Am J Pathol on May 13, 2014
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. Am J Pathol (2015) 0.99
Surgical management of giant neurofibroma in soft tissue: a single-center retrospective analysis. Int J Clin Exp Med (2015) 0.95
Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clin Cancer Res (2015) 0.93
Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr (2015) 0.85
Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab Invest (2016) 0.76
Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1. Oncotarget (2016) 0.75
Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi. Am J Transl Res (2016) 0.75
RALB provides critical survival signals downstream of Ras in acute myeloid leukemia. Oncotarget (2016) 0.75
Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget (2016) 0.75
Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene (2016) 0.75
Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. Sarcoma (2017) 0.75
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet (2009) 18.90
Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res (2005) 17.58
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer (1986) 8.57
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet (2002) 5.06
Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am (2007) 4.66
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res (2002) 4.27
The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell (1990) 4.12
NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat (2000) 3.87
Mouse models of tumor development in neurofibromatosis type 1. Science (1999) 3.40
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
Mouse tumor model for neurofibromatosis type 1. Science (1999) 2.89
CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics (2007) 2.83
Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A (1990) 2.52
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A (2002) 2.24
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg (2009) 2.04
Cancer: crime and punishment. Nature (2005) 1.91
Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell (2008) 1.86
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol (2012) 1.63
Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62
Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet (2013) 1.60
Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res (2011) 1.60
Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest (2000) 1.56
Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell (2005) 1.53
Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res (2010) 1.52
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer (1994) 1.52
ERK5: structure, regulation and function. Cell Signal (2012) 1.50
TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer (1994) 1.37
Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol (2002) 1.36
Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol (2007) 1.36
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res (2008) 1.34
Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist (2008) 1.34
Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem (2000) 1.32
Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest (2001) 1.26
p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J (2001) 1.26
Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat (2008) 1.25
Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene (2005) 1.21
Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol (1999) 1.18
Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet (1997) 1.14
Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet (2007) 1.12
Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett (2009) 1.12
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis (2005) 1.11
Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol (2009) 1.11
The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther (2005) 1.10
Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. Cancer Discov (2013) 1.10
Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas. Genes Chromosomes Cancer (1995) 1.10
Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer (1999) 1.09
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia (2007) 1.07
Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch (2001) 1.06
Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res (2002) 1.06
Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis. Oncogene (1998) 1.04
Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol (1998) 1.04
Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int (1998) 1.03
Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol (2006) 1.02
Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinog (1993) 1.01
Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer (1999) 0.99
Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res (1996) 0.96
Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. Cancer Lett (2000) 0.95
Cytogenetic findings in malignant peripheral nerve sheath tumors. Int J Cancer (1995) 0.94
PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res (2012) 0.94
Role of BMK1 in regulation of growth factor-induced cellular responses. Immunol Res (2000) 0.94
Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res (2011) 0.92
Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Hum Pathol (1997) 0.92
Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST. Sarcoma (2012) 0.90
Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Am J Pathol (2013) 0.89
p53 overexpression in the multistep process of esophageal carcinogenesis. Am J Surg Pathol (1995) 0.88
Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer (2001) 0.88
Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components. J Clin Pathol (2001) 0.87
Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: sporadic vs. neurofibromatosis-type-1-associated malignant schwannomas. Int J Cancer (1999) 0.87
Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs. Sarcoma (2008) 0.86
Multinucleated floret-like giant cells in sporadic and NF1-associated neurofibromas: a clinicopathologic study of 94 cases. Virchows Arch (2009) 0.86
Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res (2010) 0.86
Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat (2012) 0.85
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2. Virchows Arch (2009) 0.85
Modular assembly of transposon integratable multigene vectors using RecWay assembly. Nucleic Acids Res (2013) 0.84
Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression. Glia (2003) 0.84
Divergent differentiation in malignant soft tissue neoplasms: the paradigm of liposarcoma and malignant peripheral nerve sheath tumor. Int J Surg Pathol (2005) 0.83
Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet (2001) 0.83
Vascular wall cells contribute to tumourigenesis in cutaneous neurofibromas of patients with neurofibromatosis type 1. A comparative histological, ultrastructural and immunohistochemical study. Anticancer Res (2012) 0.81
The lethal prune/Killer-of-prune interaction of Drosophila causes a syndrome resembling human neurofibromatosis (NF1). Eur J Cell Biol (1992) 0.80
Expressions of various growth factors and their receptors in tissues from neurofibroma. Dermatology (2000) 0.79
Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. Surg Oncol (2013) 0.79
Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor. J Hematol Oncol (2013) 0.79
Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis. Acta Neuropathol (2014) 0.77
A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov (2015) 0.85